Item 5.02   Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
TransEnterix, Inc. (the "Company") announced that Brett Farabaugh has joined the
Company in the role of Interim Chief Financial Officer, effective January 2,
2020.
Mr. Farabaugh will serve as Interim Chief Financial Officer until April 30,
2020, with an initial annualized base salary of $300,000 and benefits offered to
executive officers. Either the Company or Mr. Farabaugh may terminate his
employment for any reason, with or without cause.
On January 2, 2020, Mr. Farabaugh received a grant of restricted stock units to
acquire 30,000 shares of the Company's common stock, which vests 90 days
following the earlier of (a) April 30, 2020, or (b) if Mr. Farabaugh's
employment is continued, the date on which Mr. Farabaugh's continued employment
begins. The grant was made under the Company's Amended & Restated Equity
Incentive Plan.
Mr. Farabaugh has served as CFO of Tryton Medical, Inc., a developer of coronary
stents based in Durham, North Carolina since August 2008, and as CEO of Tryton
Medical since August 2019. As he winds down the Tryton Medical business, Mr.
Farabaugh will continue with Tryton Medical in his current roles, which is
expected to be on a limited basis.
The foregoing description of the offer letter to Mr. Farabaugh is not complete
and is qualified in its entirety by the Offer Letter, which is attached as
Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference
herein.
Item 9.01  Financial Statements and Exhibits.
Exhibit  No.  Description
    10.1      Offer Letter, dated December 17, 2019, to Brett Farabaugh.







                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses